CheckMate 142: 5-Yr Follow-up With Nivolumab ± Ipilimumab for MSI-H/dMMR Metastatic CRC

Source: 2022 ASCO Annual Meeting*
Download Slideset
June 3-7, 2022; Chicago, Illinois
With an extended follow-up of approximately 5 years, durable clinical benefit with no new safety concerns was observed with nivolumab ± ipilimumab for patients with MSI-H/dMMR metastatic CRC.
Format: Microsoft PowerPoint (.ppt)
File Size: 189 KB
Released: June 9, 2022

Acknowledgements

Provided by Clinical Care Options, LLC
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AstraZeneca
Bristol-Myers Squibb
Daiichi Sankyo, Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings